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Summary We examined the effects of misonidazole (MISO) and recombinant human tumour necrosis factor
(rh-TNF) on tumour blood flow in mice given hyperthermic treatments. MISO (500mg kg-') or rh-TNF
(6 x I04 unit kg-') was administered intraperitoneally (i.p.) prior to hyperthermia to nude mice bearing a
xenoplanted human gastric cancer and tumour blood flow was measured by a hydrogen diffusion method
based on polarographic determinations. MISO plus hyperthermia produced a temperature-dependent decrease
in blood flow and, at 43.5C, the flow decreased to 15-30% of control and remained low for up to 24 h.
Blood flow following rh-TNF plus hyperthermia was less than that at the same temperatures following MISO
plus hyperthermia, and, at 43.5C, the flow decreased to 10-20% of control and remained low for up to 48 h.
Tumour growth delay was closely related to the duration of the decrease in blood flow. Thus, the profound
decrease in tumour blood flow following hyperthermia plus MISO or rh-TNF and the consequential tumour
regression may well be of potential clinical significance.
Increasing attention has been directed towards hyperthermia
as a treatment for patients with cancer. Heat is lethal to
malignant cells (Overgaard, 1977) and it also enhances the
antitumour efficacy of chemotherapy (Hahn, 1979). The
extent of heat damage is considerably influenced by changes
in the tissue blood flow during and after hyperthermia, as the
intra-tumoural temperature depends on blood flow in vivo in
addition to heat diffusion (Song, 1984; Eddy, 1980). Blood
flow also controls the intra-tumoural microenvironment
including tissue pH and tissue oxygen tension, which are
affected by hyperthermia (Song, 1984). When hyperthermia is
being applied, it is therefore important to consider the extent
to which this treatment alters microcirculation in the tumour.
When designing a treatment regimen for cancer, minimal
side effects and maximal antitumour effects are primary con-
siderations. A significant improvement in experimental cancer
therapy was noted when combining misonidazole (MISO), a
hypoxic-cell radiosensitiser (Adams et al., 1976) with anti-
tumour drugs or irradiation, in order to enhance the anti-
tumour effects and to reduce the dose necessary to secure the
same or better tumour response (Overgaard, 1980; Fujimoto
et al., 1988).
In a study of experimental tumours in vivo, Murray and
Randhawa (1988) found that MISO resulted in a marked
decrease in tumour blood flow in the absence of blood flow
changes in the kidney. However, when MISO is given in a
large dose, it can cause severe short-term toxicity, including
peripheral neuropathy, convulsion, and encephalopathy (Gray
et al., 1976; Saunders et al., 1978; Kun et al., 1982).
Tumour necrosis factor (TNF), an antitumour cytokine
derived from macrophages and monocytes, also reduces
blood flow in rodent tumours (Watanabel et al., 1988a, b). In
a recombinant human tumour necrosis factor (rh-TNF)
phase I study carried out in Japan, the side effects were
severe hypotension, fever with chills, and temporary throm-
bocytopenia (Taguchi, 1986). A dose of 5 x 106 unit body-'
of rh-TNF was the limit at which antagonists could be
prescribed to overcome the side effects. Thus, in the current
study, experimental doses of the drugs were chosen on the
basis of their side effects. With regard to temperature, our
hyperthermic treatment was based on thermal endurance of
patients and the limitations of apparatus used to administer
clinical hyperthermia.
In view of the enhanced antitumour efficacy of MISO or
TNF plus hyperthermia (Fujimoto et al., 1988; Watanabe et
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al., 1988a), the possibility of using hyperthermia combined
with these agents for the treatment of a human malignancy is
under consideration. To evaluate further the nature of these
interactions, the effects of these agents on tumour microcir-
culation in xenoplanted human gastric cancer tissue were
investigated.
Materials and methods
Animals and tumours
BALB/c nu/nu mice (Japan Clea Laboratories, Tokyo,
Japan) aged 5 to 6 weeks were kept under specific-pathogen-
free conditions with free access to aseptic food and water.
The animals were allocated randomly to groups of 10 to 15.
A human gastric moderately-differentiated adenocarcin-
oma, H-23, was maintained in our laboratory by serial
passage in vivo and was used between passages 39 and 47.
The H-23 tumour was transplanted by a trocar as 1 mm3
fragments, subcutaneously into the lateral part of external
root in the right hindleg, the purpose being to avoid hyper-
thermia-related damage to intra-abdominal organs. For the
mice given TNF or MISO alone, bilateral transplantation
was used.
Treatments
MISO and rh-TNF were administered to the mice i.p. in
doses of 500 mgkg-' and 6 x 104 unit kg-', respectively.
MISO and rh-TNF were provided by Dr Daniel F. Hoth
(Division of Cancer Treatment, National Cancer Inst., NIH,
Bethesda, MD, USA) and Asahi Chemical Industry Co.
(Tokyo, Japan), respectively. The specific activity of rh-TNF
was 2.4 x 106 unit mg protein-', as determined by cytotoxic
activity against mouse L-M cells (Yamazaki et al., 1986).
When the transplanted tumours grew to about 90-100
mm3 (about 2 weeks after inoculation) the treatment was
initiated. Fifty mg kg-' of Nembutal (pentobarbital-Na:
Abbott Laboratories, North Chicago, III, USA) was injected
i.p. and subsequently, rh-TNF or MISO was injected i.p.
Nembutal was also administered to the control, heat alone
and drug alone groups before measuring the blood flow.
About 10 min later, the right hindleg of the mouse was
placed in a water bath at 40.5 ± 0.1°C, 42.0 ± 0.1°C, or
43.5 ± 0.1C, for 23 min. The temperature in the centre of the
tumour equilibrated with that of the water bath within 2 to
3 min of heating (Fujimoto et al., 1988). The body core
temperature of the nude mice in the 24-25'C room experi-
ments remained at 28°C during the hyperthermia.
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Tumour growth and tissue bloodflow
Two perpendicular diameters (length and width) of the trans-
planted tumours were measured on alternate days using a
vernier sliding caliper and the tumour volume was calculated
as 1/2 x ab2, where a and b are the longest and shortest
diameters, respectively. Since the tumour volumes at the start
of the study differed between mice, the ratio of tumour
volume at a given time to intial tumour volume was calcu-
lated for each mouse and the mean ± s.d. was calculated for
each group.
Tumour doubling time, i.e., the time required to reach
twice the volume at the first treatment, was calculated for the
12 experimental groups. In mice given heat at 42.0°C or
43.5°C together with rh-TNF, the tumour growth curve did
not achieve this end point, therefore we extrapolated the
growth curve for purposes of calculation. The effect of the
different treatments was evaluated by tumour growth delay.
To assess the effects of MISO and rh-TNF on microcircu-
lation in the H-23 tumours, tissue blood flow was measured
consecutively in each mouse by a hydrogen diffusion method
(Aukland et al., 1964). The method is based on the polaro-
graphic determination of the amount of hydrogen gas reach-
ing a 0.3 mm diameter platinum electrode which had been
inserted (5 min after Nembutal injection) into the tumour
through the subcutaneous tissue in the dorsum.
Hydrogen saturation of the tissues was achieved by allow-
ing the mice to breathe hydrogen gas together with air, which
was regulated and checked by a hydrogen gas controller
(Model SHI-102, Unique Medical Co., Tokyo, Japan). The
hydrogen clearance curve in the H-23 tumour tissue was
computed by a digital UH-meter (Model MHG-D1, Unique
Medical Co.) based on a Zierler's theory (1965) and, the
value of tissue blood flow was given at one second intervals
by a digital computer connected to the UH-meter.
Tumour blood flow in the control mice was measured in
the same manner for all three temperatures and for normo-
temperature plus anaesthesia alone. The area under the curve
(AUC) of blood flow was calculated by the trapezoidal rule
for both 24h and 6 days following the end of treatment.
Statistical difference was determined using Student's t-test.
Results
Prehyperthermic blood flow in the H-23 tumours was 30.8 ±
7.9 (mean ± s.d.) ml min-' 100 g-' and tumour blood flow in
the control group at the end of study was 27.6 ± 6.1 ml
min' 100 g-'. In contrast, the flow in muscle tissues of the
hindleg was 50.7 ± 7.1 ml min ' 100 g '.
Effect ofhyperthermia, MISO or rh-TNF on bloodflow
As shown in Figure la, during application of heat 40.5°C,
42.0°C, or 43.5°C, the muscle blood flow increased to 144%,
163%, and 201% respectively and then, post-hyperthermic-
ally, it reverted to the pre-treatment value with a slight,
transient decrease in the case of42.0°C or 43.5°C (Figure la).
The area under the curve (AUC) values for 24 h following
40.5°C, 42.5°C and 43.5°C were 73.7, 73.5, and 74.4 1100 g-',
respectively.
In contrast, blood flow in the H-23 tumour increased
slightly during heat treatment and subsequently decreased
dependent upon the temperature, that is, to 83% following
40.5°C, 68% following 42.0°C, and 36% following 43.5°C.
There was a gradual recovery 5-6 h after termination of the
hyperthermia. The AUC values for 24 h following 40.5°C and
42.0°C were 41.9 and 43.7 1100g' respectively, and in the
case of 43.5°C, the AUC decreased to 90.5% of that for
40.5°C.
Figure lb shows changes in tumour blood flow due to
MISO or rh-TNF. rh-TNF but not MISO led to a significant
reduction in blood flow 2-4 h after administration (0.022<
P<0.047). However, the AUC values for 24 h following
rh-TNF or MISO administration were 42.1 and 45.5 1
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Figure 1 Time course of blood flow in a the muscle tissue ((D,
m, A) and H-23 tumour (0, 0, A) during and after hyperther-
mic treatment at 40.5°C, 42.0C and 43.5°C, and that in b H-23
tumour after an i.p. administration of MISO 500 mgkg-' and
rh-TNF 6 x 104 unitkg-'. Symbols: a, 0, (1) 40.5°C; 0, C
42.0°C; A, A 43.5°C. b, O MISO; OD rh-TNF. Results are
mean±s.d. using pooled data from 10-15 mice.
100g-I respectively. On the other hand, the dose of Nem-
butal which we used did not alter the tumour blood flow
(data not shown).
Effect ofMISO combined with hyperthermia on tumour bloodflow
Figure 2a shows the time course of blood flow in the H-23
tumour treated with MISO plus heat. The AUC values for
24 h following 40.5°C, 42.0°C, and 43.5°C were 37.7, 33.0 and
10.4 1100g- respectively, these values being 89.9%, 75.6%
and 26.2% of those for heat alone. The AUC values at these
temperatures were 82.9%, 72.6% and 22.8% respectively of
those for MISO alone.
Effect ofrh-TNFcombined with hyperthermia on tumour bloodflow
As shown in Figure 2b, the AUC values for 24 h of tumour
blood flow in mice given rh-TNF plus hyperthermia were
24.9, 20.8, and 14.41 100 g' at 40.5°C, 42.0°C, and 43.5°C
respectively. These are equivalent to 59.4%, 47.6% and
36.5% respectively of the values for hyperthermia alone and
59.1%, 49.4% and 34.2% of the value for rh-TNF alone.
Comparison oftumour bloodflowfor heat combined with
MISO or with rh-TNF
As shown in Figure 2, the AUC values of tumour blood flow
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Figure 2 Time course of tumour blood flow during and after a
MISO 500mgkg-' plus heat at 40.5°C, 42.0OC and 43.5'C; b
rh-TNF 6 x I04 unit kg-' plus heat at 40.5°C, 42.0°C and 43.5°C.
Ob, 40 40.5°C; Ii, EO 42.0°C; A, A 43.5°C. Results are mean±
s.d. using pooled data from 10-15 mice. The dotted line indicates
tumour blood flow with a MISO only and b rh-TNF only given.
and 42.0°C were 65.9% and 62.9%, of the corresponding
values for MISO plus hyperthermia. With respect to findings
with each drug plus hyperthermia at 43.5°C, the AUC for 6
days of tumour blood flow for rh-TNF plus heat was 142.41
100g-', whereas that for MISO plus heat was 190.41
100 g-', as shown in Figure 2.
a b c
'I
u.0r, I * * , , L ---A..
0 4 8 0 4 8 0 4 8
Days after treatment
Figure 3 Comparison of time course of relative tumour growth
in each group. Results are mean±s.d. using pooled data obtained
from 10-15 mice. Symbols: a, 0 controls; 0 40.5°C; 0 42.0°C;
A 43.5°C; b * MISO alone; 0 MISO plus 40.5°C; 0 MISO
plus 42.0C; A MISO plus 43.5°C; c 0 rh-TNF alone; 0 rh-
TNF plus 40.5°C; 0 rh-TNF plus 42.0°C; A rh-TNF plus
43.5°C.
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Figure 4 Correlation between tumour growth delay and AUC
for 24 h. Symbols: x controls; Q MISO alone; e rh-TNF alone;
0 40.5°C; 0 42.0°C; A 43.5°C; Oi MISO plus 40.5°C; O MISO
plus 42.0C; A MISO plus 43.5°C; O rh-TNF plus 40.5°C; *J
rh-TNF plus 42.0OC; A rh-TNF plus 43.5°C.
Relative tumour growth in each group
As shown in Figure 3, tumour growth delay in the MISO
alone and rh-TNF alone treated groups was 0.7 and 1.5 days
respectively and for hyperthermia alone at 40.5°C, 42.0GC
and 43.5°C, tumour growth delay was 1.5, 2.2 and 3.4 days
respectively.
With MISO plus heat at 40.5°C, 42.5°C or 43.5°C, growth
delays were 2.7 and 4.4 days and 10.2 days. With rh-TNF
plus heat, 6.7 and 8.2 day growth delays were observed
for 40.5°C and 42.0°C, respectively (Figure 3).
On the other hand, in five out of 12 mice (42%) given
hyperthermia at 43.5°C plus rh-TNF, there was complete
tumour regression and absence of any tumour re-growth 60
days after the treatment. In mice given hyperthermia at
43.5°C plus MISO, however, complete regression did not
occur.
Correlation between tumour bloodflow and tumour growth
To examine the correlation between treatment effects on
tumour blood flow and a tumour growth, the AUC for 24 h
was compared with delay in tumour growth for each group.
As shown in Figure 4, with AUC showed an inverse correla-
tion (P = -0.72) with tumour growth delay. (In the case of
43.5°C plus rh-TNF, where local tumour control was pro-
duced in 5/12 mice, a mean of the tumour growth delay in
the remaining seven mice was plotted.)
Discussion
When MISO and rh-TNF were administered concomitantly
with hyperthermia to tumour-bearing mice, the favourable
antitumour effect was in proportion to the marked decrease
in the post-hyperthermic blood flow in the tumours.
Whereas it has been previously shown that MISO enhances
antitumour efficacy of hyperthermia (Stratford & Adams,
1977; Bleehen et al., 1977; Hall et al., 1977; Honess et al.,
1978) the underlying mechanisms have remained to be clari-
fied. Murray and Randhawa (1988) reported that a single
dose of MISO (1000 mg kg-') reduced blood flow in two
different murine tumours. When the MISO dose was reduced
to 500 mgkg-', the effect was lost in one tumour but not in
the other. In the current study, the i.p. administration of
MISO (500 mgkg') to mice with an H-23 tumour did not
decrease the AUC of the tumour blood flow.
The data for hyperthermia alone in the current study
indicate that there is a relationship between AUC for 24 h in
tumour tissues and tumour growth, that is, when the AUC is
less, the growth delay is prolonged. The same is also true for
the combination of hyperthermia plus MISO, as shown in
Figure 4. Figures 2a and 3 show that marked decrease in
blood flow due to hyperthermia at 43.5°C plus MISO result-
ed in a prolonged delay in re-growth, without a permanent
local control of tumour. A vascular occlusion method
employing a D-shaped metal clamp was used by Denekamp36 S. FUJIMOTO et al.
et al. (1983) to study the relation between interruption of
tumour blood flow and tumour cell death. They reported
that vascular occlusion for 2-8 h induced a progressive delay
in tumour growth, findings in good agreement with ours.
TNF is defined as a protein producing haemorrhagic
necrosis of experimental tumours and having cytocidal effects
on tumour cells, in vitro (Matthews & Watkins, 1978; Sugar-
man et al., 1985; Creasey et al., 1987; Shine et al., 1989).
TNF also has a cytotoxic effect on bovine aortic endothelial
cells in culture (Nawroth & Stern, 1986). Although 6 x 104
unit kg-' of rh-TNF did reduce the tumour blood flow, the
reduction in AUC for 24 h was small compared with that for
MISO alone (Figure lb).
Fujimoto et al. (1991) reported that hyperthermia together
with rh-TNF given to nude mice in vivo produced greater
antitumour efficacy, than either hyperthermia or rh-TNF
alone. In the present study the temperature dependence of
this antitumour effect and the concomitant blood flow reduc-
tion were studied. The AUC values for blood flow (24 h)
following heat and rh-TNF decreased with increasing temp-
erature; for example the AUC for 43.50C was 69% of that
for 420C. The effect on blood flow of heat plus rh-TNF was
shown to be greater than that of heat plus MISO, the AUC
(6 days) following treatment with 43.5°C plus rh-TNF being
25% less than that following 43.5°C plus MISO.
Denekamp et al. (1983) reported that vascular occlusion in
excess of 24 h resulted in a complete local control in 100% of
the tumour-bearing animals. In the current study, a marked
decrease in blood flow for 24 h or 6 days was seen in the
group exposed to heat at 43.5°C and given rh-TNF. The
decrease in AUC for tumour blood flow for 6 days, in this
group was 25%, compared with the case of mice given heat
at 43.5°C and MISO. As there was complete local tumour
control in five of 12 mice given heat at 43.5°C plus rh-TNF,
this finding is also in accordance with that reported by
Denekamp et al. (1983).
Synergism between heat and these two drugs is indicated
by our data for both tumour blood flow and tumour growth
delay, although this was not determined mathematically.
When rh-TNF was given together with heat at 43.5°C, there
was a remarkable reduction in blood flow and a complete
regression of tumour in 5/12 mice followed. These results
may be due partly to the decrease in tumour blood flow
owing to the enhanced effect of rh-TNF by hyperthermia (on
the newly-formed tumour vessels) and partly to the combined
cytotoxic effects of rh-TNF and hyperthermia. Combined
treatment with hyperthermia and rh-TNF or MISO seems
worthy of further consideration for the treatment of human
malignancy.
We thank M. Ohara for valuable comments.
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